• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Racial differences in cardiopulmonary outcomes of hospitalized COVID-19 patients with acute kidney injury.住院 COVID-19 合并急性肾损伤患者的心肺结局的种族差异。
Rev Cardiovasc Med. 2021 Dec 22;22(4):1667-1675. doi: 10.31083/j.rcm2204174.
2
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.用于治疗 COVID-19 的 SARS-CoV-2 中和单克隆抗体。
Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.
3
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦片/利托那韦片组合包装用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2.
4
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
5
RECOVID: Retrospective Observational Study of Renal Outcomes and Long-Term Mortality in Patients With COVID-19-Associated AKI, A Comparison Between Vaccinated and Unvaccinated Patients.RECOVID:COVID-19相关性急性肾损伤患者肾脏结局和长期死亡率的回顾性观察研究,接种疫苗与未接种疫苗患者的比较
Kidney Med. 2025 Jun 18;7(7):101020. doi: 10.1016/j.xkme.2025.101020. eCollection 2025 Jul.
6
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦/利托那韦片用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD015395. doi: 10.1002/14651858.CD015395.pub3.
7
Anticoagulants for people hospitalised with COVID-19.COVID-19 住院患者的抗凝治疗。
Cochrane Database Syst Rev. 2022 Mar 4;3(3):CD013739. doi: 10.1002/14651858.CD013739.pub2.
8
Colchicine for the treatment of COVID-19.秋水仙碱治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Oct 18;10(10):CD015045. doi: 10.1002/14651858.CD015045.
9
Convalescent plasma for people with COVID-19: a living systematic review.COVID-19 患者恢复期血浆治疗:一项实时系统评价。
Cochrane Database Syst Rev. 2023 May 10;5(5):CD013600. doi: 10.1002/14651858.CD013600.pub6.
10
Convalescent plasma for people with COVID-19: a living systematic review.COVID-19 患者恢复期血浆治疗:一项实时系统评价。
Cochrane Database Syst Rev. 2023 Feb 1;2(2):CD013600. doi: 10.1002/14651858.CD013600.pub5.

引用本文的文献

1
Health inequalities and outcomes following acute kidney injury: a systematic review & meta-analyses of observational studies.急性肾损伤后的健康不平等与结局:观察性研究的系统评价和荟萃分析
BMC Nephrol. 2025 Aug 27;26(1):494. doi: 10.1186/s12882-025-04391-x.
2
Global geographic and socioeconomic disparities in COVID-associated acute kidney injury: a systematic review and meta-analysis.新冠相关急性肾损伤的全球地理和社会经济差异:一项系统综述和荟萃分析。
J Glob Health. 2025 Jul 25;15:04166. doi: 10.7189/jogh.15.04166.

本文引用的文献

1
[Acute kidney injury in patients hospitalized with COVID-19 in Wuhan, China: a single-center retrospective observational study].[中国武汉新冠肺炎住院患者的急性肾损伤:一项单中心回顾性观察研究]
Nan Fang Yi Ke Da Xue Xue Bao. 2021 Feb 25;41(2):157-163. doi: 10.12122/j.issn.1673-4254.2021.02.01.
2
Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases.血管紧张素转换酶2与心脏肾脏疾病中的新型冠状病毒肺炎
Clin Sci (Lond). 2021 Jan 15;135(1):1-17. doi: 10.1042/CS20200482.
3
COVID-19 and Acute Kidney Injury: A Systematic Review and Meta-Analysis.新型冠状病毒肺炎与急性肾损伤:一项系统评价与荟萃分析
Pathogens. 2020 Dec 15;9(12):1052. doi: 10.3390/pathogens9121052.
4
Pathophysiology and Pathology of Acute Kidney Injury in Patients With COVID-19.新型冠状病毒肺炎患者急性肾损伤的病理生理学和病理学。
Adv Chronic Kidney Dis. 2020 Sep;27(5):365-376. doi: 10.1053/j.ackd.2020.09.003. Epub 2020 Oct 20.
5
Acute Kidney Injury in a National Cohort of Hospitalized US Veterans with COVID-19.美国 COVID-19 住院退伍军人队列中的急性肾损伤。
Clin J Am Soc Nephrol. 2020 Dec 31;16(1):14-25. doi: 10.2215/CJN.09610620. Epub 2020 Nov 16.
6
Stratification of Acute Kidney Injury in COVID-19.新型冠状病毒肺炎相关急性肾损伤的分层。
Am J Trop Med Hyg. 2020 Dec;103(6):2164-2167. doi: 10.4269/ajtmh.20-0794. Epub 2020 Oct 27.
7
Lopinavir-Ritonavir Associated Acute Kidney Injury Is Not Related to Crystalluria in Critically Ill COVID-19 Patients.洛匹那韦-利托那韦相关急性肾损伤与危重症COVID-19患者的结晶尿无关。
Kidney Int Rep. 2020 Nov;5(11):2119. doi: 10.1016/j.ekir.2020.08.021. Epub 2020 Aug 26.
8
Acute Kidney Injury Associated With Lopinavir/Ritonavir Combined Therapy in Patients With COVID-19.新冠病毒疾病患者中洛匹那韦/利托那韦联合治疗相关的急性肾损伤
Kidney Int Rep. 2020 Oct;5(10):1787-1790. doi: 10.1016/j.ekir.2020.07.035. Epub 2020 Aug 6.
9
Oxalate Nephropathy Caused by Excessive Vitamin C Administration in 2 Patients With COVID-19.2例新型冠状病毒肺炎患者因过量服用维生素C导致草酸盐肾病
Kidney Int Rep. 2020 Oct;5(10):1815-1822. doi: 10.1016/j.ekir.2020.07.008. Epub 2020 Jul 16.
10
Clinicopathological Features and Outcomes of Acute Kidney Injury in Critically Ill COVID-19 with Prolonged Disease Course: A Retrospective Cohort.危重症 COVID-19 患者中急性肾损伤的临床病理特征和结局:一项回顾性队列研究。
J Am Soc Nephrol. 2020 Sep;31(9):2205-2221. doi: 10.1681/ASN.2020040426. Epub 2020 Aug 21.

住院 COVID-19 合并急性肾损伤患者的心肺结局的种族差异。

Racial differences in cardiopulmonary outcomes of hospitalized COVID-19 patients with acute kidney injury.

机构信息

Division of Cardiovascular Medicine, Ohio State University, Columbus, OH 43210, USA.

Department of Internal Medicine, Morehouse School of Medicine, Atlanta, GA 30310, USA.

出版信息

Rev Cardiovasc Med. 2021 Dec 22;22(4):1667-1675. doi: 10.31083/j.rcm2204174.

DOI:10.31083/j.rcm2204174
PMID:34957809
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9054458/
Abstract

In-hospital acute kidney injury (IH-AKI) has been reported in a significant proportion of patients with COVID-19 and is associated with increased disease burden and poor outcomes. However, the mechanisms of injury are not fully understood. We sought to determine the significance of race on cardiopulmonary outcomes and in-hospital mortality of hospitalized COVID-19 patients with AKI. We conducted a retrospective cohort study of consecutive patients hospitalized in Grady Health System in Atlanta, Georgia between February and July 2020, who tested positive for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) on qualitative polymerase-chain-reaction assay. We evaluated the primary composite outcome of in-hospital cardiac events, and mortality in blacks with AKI versus non-blacks with AKI. In a subgroup analysis, we evaluated the impact of AKI in all blacks and in all non-blacks. Of 293 patients, effective sample size was 267 after all exclusion criteria were applied. The mean age was 61.4 ± 16.7, 39% were female, and 75 (28.1%) had IH-AKI. In multivariable analyses, blacks with IH-AKI were not more likely to have in-hospital cardiac events (aOR 0.3, 95% Confidence interval (CI) 0.04-1.86, = 0.18), require ICU stay (aOR 0.80, 95% CI 0.20-3.25, = 0.75), acute respiratory distress syndrome (aOR 0.77, 95% CI 0.16-3.65, = 0.74), require mechanical ventilation (aOR 0.51, 95% CI 0.12-2.10, = 0.35), and in-hospital mortality (aOR 1.40, 95% CI 0.26-7.50, = 0.70) when compared to non-blacks with IH-AKI. Regardless of race, the presence of AKI was associated with worse outcomes. Black race is not associated with higher risk of in-hospital cardiac events and mortality in hospitalized COVID-19 patients who develop AKI. However, blacks with IH-AKI are more likely to have ARDS or die from any cause when compared to blacks without IH-AKI.

摘要

住院期间急性肾损伤(IH-AKI)在 COVID-19 患者中占很大比例,与疾病负担增加和不良预后相关。然而,损伤的机制尚不完全清楚。我们旨在确定种族对 COVID-19 合并 AKI 住院患者心肺结局和院内死亡率的意义。

我们对 2020 年 2 月至 7 月在佐治亚州亚特兰大 Grady 卫生系统住院并通过定性聚合酶链反应检测出严重急性呼吸综合征冠状病毒-2(SARS-CoV-2)阳性的连续患者进行了回顾性队列研究。我们评估了黑人 AKI 与非黑人 AKI 患者住院期间心脏事件和死亡率的主要复合结局。在亚组分析中,我们评估了 AKI 在所有黑人患者和所有非黑人患者中的影响。

在 293 名患者中,所有排除标准适用后,有效样本量为 267 名。患者平均年龄为 61.4 ± 16.7 岁,39%为女性,75 名(28.1%)患有 IH-AKI。多变量分析显示,黑人 IH-AKI 患者发生院内心脏事件的可能性并不高于非黑人(比值比 0.3,95%置信区间 0.04-1.86, = 0.18),需要入住 ICU(比值比 0.80,95%置信区间 0.20-3.25, = 0.75)、急性呼吸窘迫综合征(比值比 0.77,95%置信区间 0.16-3.65, = 0.74)、需要机械通气(比值比 0.51,95%置信区间 0.12-2.10, = 0.35)和院内死亡率(比值比 1.40,95%置信区间 0.26-7.50, = 0.70)。

与非黑人 IH-AKI 患者相比,无论种族如何,AKI 的存在与更差的结局相关。在 COVID-19 合并 AKI 住院患者中,黑人种族与院内心脏事件和死亡率的风险增加无关。然而,与没有 IH-AKI 的黑人相比,黑人 IH-AKI 患者更有可能发生急性呼吸窘迫综合征或任何原因导致的死亡。